Diencephalic gliomas may be grouped into 2 clinical categories. Optic pathway/hypothalamus gliomas (OPG) arise primarily from a slower-growing juvenile pilocytic astrocytoma, and thalamic gliomas arise primarily from a fibrillary astrocytoma which can become clinically and histologically more aggressive. Children with OPG have an excellent long-term prognosis with a 10-year survival of over 85%. The major therapeutic challenge for these patients is to maximize their quality of life by preserving visual and endocrine function while minimizing treatment-related morbidity. Treatment is often initiated at diagnosis in infants and toddlers who have a major visual impairment or the diencephalic syndrome. The judicious application of chemotherapy may serve to forestall the need for radiotherapy or surgery. Children with neurofibromatosis-1 (NF-1) usually have a more indolent course. Tumors may grow more slowly or occasionally regress spontaneously. However, over 90% of children with OPG without NF-1 will require some form of therapy. Patients with thalamic gliomas present with a shorter history, often with hydrocephalus. Surgical intervention is often required to relieve intracranial pressure and establish the histologic identity of the tumor. Over 75% of these tumors will become locally aggressive. Current multimodality therapy is relatively ineffective. The bithalamic variant behaves similarly to a pontine glioma.

Keywords:
Optic pathway glioma, Diencephalic tumor, Thalamic tumor, Neurofibromatosis
1.
Stiller CA, Nectoux J: International incidence of childhood brain and spinal tumours. Int J Epidemiol 1994;23:458–464.
2.
Hjalmars U, Kulldorff M, Wahlqvist Y, Lannering B: Increased incidence rates but no space-time clustering of childhood astrocytoma in Sweden, 1973–1992: A population-based study of pediatric brain tumors. Cancer 1999;85:2077–2090.
3.
Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86:747–754.
4.
Janss A, Grundy R, Cnaan A, Savino P, Packer R: Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer 1995;75:1051–1059.
5.
Finlay J, Boyett J, Yates A, Wisoff J, Milstein J, Geyer J, Bertolone S, McGuire P, Cherlow J, Tefft M, Turski P, Wara W, Edwards M, Sutton L, Berger M, Epstein F, Ayers G, Allen J, Packer R: Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol 1995;13:112–123.
6.
Reardon DA, Gajjar A, Sanford RA, Heideman RL, Walter AW, Thompson SJ, Merchant TE, Li H, Jenkins JJ, Langston J, Boyett JM, Kun LE: Bithalamic involvement predicts poor outcome among children with thalamic glial tumors. Pediatr Neurosurg 1998;29:29–35.
7.
Listernick R, Charrow J, Greewald MJ, Esterly NB: Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989;114:788–792.
8.
Alvord E, Lofton S: Gliomas of the optic nerve or chiasm. Outcome by patients’ age, tumor site and treatment. J Neurosurg 1988;68:85–98.
9.
Tao ML, Barnes PD, Billett AL, Leong T, Shrieve DC, Scott RM, Tarbell NJ: Childhood optic chiasm gliomas: Radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys 1997;39:579–587.
10.
Packer R, Lange B, Ater J, Nicholson H, Allen J, Walker R, Prados M: Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993;11:850–856.
11.
Arnoldi KA, Tychsen L: Prevalence of intracranial lesions in children intially diagnosed with disconjugate nystagmus (published erratum appears in J Pediatr Ophthalmol Strabismus 1995 Nov–Dec;32(6):347). J Pediatr Opthalmol Strabismus 1995;32:296–301.
12.
DeSousa AL, Kalsbeck JE, Mealey J Jr, Fitzgerald J: Diencephalic syndrome and its relation to opticochiasmatic glioma: Review of twelve cases. Neurosurgery 1979;4:207–209.
13.
Poussaint Ty, Barnes PD, Nichols K, Anthony DC, Cohen L, Tarbell NJ, Goumnerova L: Diencephalic syndrome: Clinical features and imaging findings. Am J Neuroradiol 1997;18:1499–1505.
14.
Burr IM, Slonim AE, Danish RK, Gadoth N, Butler IJ: Diencephalic syndrome revisited. J Pediatr 1976;88:439–444.
15.
Wisoff JH: Management of optic pathway tumors of childhood. Neursurg Clin North Am 1992;3:791–802.
16.
Gropman AL, Packer RJ, Nicholson HS, Vezinia LG, Jakacki R, Geyer R, Olson JM, Phillips P, Needle M, Broxson EH Jr, Reaman G, Finaly J: Treatment of diencephalic syndrome with chemotherapy: Growth, tumor response, and long term control. Cancer 1998;83:166–172.
17.
Civitello L, Packer R, Rorke L, Siegel K, Sutton L, Schut L: Leptomeningeal dissemination of low-grade gliomas in childhood. Neurology 1988;38:562–566.
18.
Gajjar A, Bhargava R, Jenkins JJ, Heideman R, Sanford RA, Langston JW, Walter AW, Kuttesch JF, Muhlbauer M, Kun LE: Low-grade astrocytoma with neuraxis dissemination at diagnosis. J Neurosurg 1995;83:67–71.
19.
Listernick R, Charrow J, Greenwald M, Mets M: Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study (see comments). J Pediatr 1994;125:63–66.
20.
Housepian EM, Chi TL: Neurofibromatosis and optic pathways gliomas. J Neurooncol 1993;15:51–55.
21.
Deliganis AV, Geyer JR, Berger MS: Prognostic significance of type 1 neurofibromatosis (von Recklinghausen disease) in childhood optic glioma. Neurosurgery 1996;38:1114–1118; discussion 1118–1119.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.